Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Progress and pitfalls of a year of drug repurposing screens against COVID-19
Julien Sourimant, Megha Aggarwal, Richard K. Plemper
Current Opinion in Virology (2021) Vol. 49, pp. 183-193
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters
Michihito Sasaki, Koshiro Tabata, Mai Kishimoto, et al.
Science Translational Medicine (2022) Vol. 15, Iss. 679
Open Access | Times Cited: 79
Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses
Judith M. White, Joshua T. Schiffer, Rachel Bender Ignacio, et al.
mBio (2021) Vol. 12, Iss. 6
Open Access | Times Cited: 58
Mechanisms of action of repurposed Ebola virus antivirals – the roles of phospholipidosis and cholesterol homeostasis
Jamie A. Kelly, Virginia Aida-Ficken, Laura K. McMullan, et al.
Antiviral Research (2025), pp. 106167-106167
Closed Access | Times Cited: 1
Development and optimization of a high‐throughput screening assay for in vitro anti‐SARS‐CoV‐2 activity: Evaluation of 5676 Phase 1 Passed Structures
Winston Chiu, Lore Verschueren, Christel Van den Eynde, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 7, pp. 3101-3111
Open Access | Times Cited: 17
Target-Based Virtual Screening and LC/MS-Guided Isolation Procedure for Identifying Phloroglucinol-Terpenoid Inhibitors of SARS-CoV-2
Bo Hou, Yumin Zhang, Hanyi Liao, et al.
Journal of Natural Products (2022) Vol. 85, Iss. 2, pp. 327-336
Closed Access | Times Cited: 16
An allosteric mechanism for potent inhibition of SARS-CoV-2 main proteinase
Yunju Zhang, Jingjing Guo, Yang Liu, et al.
International Journal of Biological Macromolecules (2024) Vol. 265, pp. 130644-130644
Closed Access | Times Cited: 3
Large-scale Deep Learning Identifies the Antiviral Potential of PKI-179 and MTI-31 Against Coronaviruses
Demi van der Horst, Madalina E. Carter-Timofte, Adeline Danneels, et al.
Antiviral Research (2024) Vol. 231, pp. 106012-106012
Open Access | Times Cited: 3
Influenza viruses and coronaviruses: Knowns, unknowns, and common research challenges
Olivier Terrier, Mustapha Si‐Tahar, Mariette Ducatez, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 12, pp. e1010106-e1010106
Open Access | Times Cited: 20
4′-Fluorouridine Is a Broad-Spectrum Orally Available First-Line Antiviral That May Improve Pandemic Preparedness
Carolin M. Lieber, Richard K. Plemper
DNA and Cell Biology (2022) Vol. 41, Iss. 8, pp. 699-704
Open Access | Times Cited: 14
Oral administration of S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and accelerates recovery from clinical aspects of COVID-19
Michihito Sasaki, Koshiro Tabata, Mai Kishimoto, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 12
KGML-xDTD: a knowledge graph–based machine learning framework for drug treatment prediction and mechanism description
Chunyu Ma, Zhihan Zhou, Han Liu, et al.
GigaScience (2022) Vol. 12
Open Access | Times Cited: 12
Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy
Tonino Alonzi, Alessandra Aiello, Linda Petrone, et al.
Cells (2021) Vol. 11, Iss. 1, pp. 52-52
Open Access | Times Cited: 16
Does the public know when a scientific controversy is over? Public perceptions of hydroxychloroquine in France between April 2020 and June 2021
Émilien Schultz, Laëtitia Atlani-Duault, Patrick Peretti‐Watel, et al.
Therapies (2022) Vol. 77, Iss. 5, pp. 591-602
Open Access | Times Cited: 11
Repurposing of Drugs for SARS-CoV-2 Using Inverse Docking Fingerprints
Marko Jukič, Katarina Kores, Dušanka Janežič, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 14
Probing the Action of Screened Anticancer Triazole–Tetrazole Derivatives Against COVID-19 Using Molecular Docking and DFT Investigations
Rageh K. Hussein, Ghada A. Khouqeer, A. Alkaoud, et al.
Natural Product Communications (2022) Vol. 17, Iss. 5, pp. 1934578X2210939-1934578X2210939
Open Access | Times Cited: 8
KGML-xDTD: A Knowledge Graph-based Machine Learning Framework for Drug Treatment Prediction and Mechanism Description
Chunyu Ma, Zhihan Zhou, Han Liu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 7
Real-world Efficacy of Ensitrelvir in Hospitalized Patients with COVID-19 in Japan: A Retrospective Observational Study
Ryohei Yoshida, Takaaki Sasaki, Yoshinobu Ohsaki
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Transitioning from Crisis to Control: Reviewing Antiviral Agents Targeting Pandemic Viruses
Deepali Nahar, Sayali Ayare, Meena Kanyalkar
Future Virology (2024), pp. 1-19
Closed Access | Times Cited: 1
Exploring DrugCentral: from molecular structures to clinical effects
Liliana Halip, Sorin Avram, Ramona Curpăn, et al.
Journal of Computer-Aided Molecular Design (2023) Vol. 37, Iss. 12, pp. 681-694
Open Access | Times Cited: 3
Oral delivery of a host-directed antiviral, niclosamide, as a cholate-coated nanoformulation
Chongkai Zhai, Mingda Wang, Yanyan Jin, et al.
International Journal of Antimicrobial Agents (2023) Vol. 62, Iss. 5, pp. 106973-106973
Closed Access | Times Cited: 3
A SARS-CoV-2 mini-genome assay based on negative-sense RNA to study replication inhibitors and emerging mutations
Thomas Vial, Michael S. Oade, Colin A. Russell, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 4
Public perceptions of the association between drug effectiveness and drug novelty in France during the COVID-19 pandemic
Émilien Schultz, Léo Mignot, Jeremy K. Ward, et al.
Therapies (2022) Vol. 77, Iss. 6, pp. 693-701
Open Access | Times Cited: 3
Structurally Modified Bioactive Peptide Inhibits SARS-CoV-2 Lentiviral Particles Expression
Khushwant S. Bhullar, Manal A. Nael, Khaled M. Elokely, et al.
Pharmaceutics (2022) Vol. 14, Iss. 10, pp. 2045-2045
Open Access | Times Cited: 3
Understanding COVID-19 Pathogenesis: A Drug-Repurposing Effort to Disrupt Nsp-1 Binding to Export Machinery Receptor Complex
Sona Vasudevan, James N. Baraniuk
Pathogens (2021) Vol. 10, Iss. 12, pp. 1634-1634
Open Access | Times Cited: 3
Editorial overview: Special issue on antiviral strategies in Current Opinion in Virology
Richard K. Plemper
Current Opinion in Virology (2021) Vol. 50, pp. 95-96
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top